Freestone Grove Partners LP Makes New $2.22 Million Investment in Maximus, Inc. $MMS

Freestone Grove Partners LP bought a new stake in Maximus, Inc. (NYSE:MMS) in the second quarter, HoldingsChannel.com reports. The institutional investor bought 41,332 shares of the health services provider’s stock, valued at approximately $2,222,000.

A number of other institutional investors have also made changes to their positions in the business. Farther Finance Advisors LLC lifted its position in Maximus by 69.0% during the 4th quarter. Farther Finance Advisors LLC now owns 284 shares of the health services provider’s stock worth $25,000 after buying an additional 116 shares in the last quarter. Advisory Services Network LLC bought a new position in shares of Maximus in the third quarter worth about $32,000. Northwestern Mutual Wealth Management Co. raised its stake in shares of Maximus by 225.2% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 439 shares of the health services provider’s stock worth $38,000 after acquiring an additional 304 shares during the last quarter. Canada Pension Plan Investment Board acquired a new position in shares of Maximus during the second quarter worth approximately $35,000. Finally, Danske Bank A S acquired a new position in shares of Maximus during the third quarter worth approximately $55,000. 97.21% of the stock is owned by institutional investors.

Maximus Stock Up 0.3%

Shares of Maximus stock opened at $59.73 on Friday. The company has a quick ratio of 2.42, a current ratio of 2.42 and a debt-to-equity ratio of 0.90. Maximus, Inc. has a 12 month low of $52.73 and a 12 month high of $100.00. The business has a fifty day simple moving average of $57.66 and a 200 day simple moving average of $63.63. The stock has a market cap of $3.13 billion, a PE ratio of 8.82 and a beta of 0.59.

Maximus (NYSE:MMS) last released its earnings results on Thursday, August 6th. The health services provider reported $2.22 earnings per share for the quarter, beating the consensus estimate of $2.21 by $0.01. Maximus had a return on equity of 24.91% and a net margin of 7.07%.The firm had revenue of $1.28 billion for the quarter, compared to analyst estimates of $1.33 billion. During the same quarter in the prior year, the firm posted $2.16 earnings per share. The company’s quarterly revenue was down 5.1% on a year-over-year basis. Maximus has set its FY 2026 guidance at 7.900-8.200 EPS. Research analysts predict that Maximus, Inc. will post 8.03 EPS for the current year.

Maximus Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, August 31st. Investors of record on Friday, August 14th will be given a $0.33 dividend. This represents a $1.32 dividend on an annualized basis and a dividend yield of 2.2%. The ex-dividend date is Friday, August 14th. Maximus’s dividend payout ratio (DPR) is currently 19.50%.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on MMS shares. Zacks Research lowered shares of Maximus from a “hold” rating to a “strong sell” rating in a report on Tuesday, August 11th. Wall Street Zen downgraded Maximus from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of Maximus in a research note on Monday, August 17th. One equities research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Maximus presently has an average rating of “Reduce”.

Trending Headlines about Maximus

Here are the key news stories impacting Maximus this week:

• Positive Sentiment: Zacks raised its FY2028 EPS forecast to $9.15 from $8.94, while also increasing estimates for Q1 2028, Q2 2028 and Q3 2028. The revisions suggest expectations for longer-term earnings growth remain intact.
• Neutral Sentiment: The analyst made several offsetting changes to its forecasts, including higher estimates for Q2 2027 and lower estimates for Q1 2027, Q3 2027 and Q4 2027. Zacks projects FY2027 EPS of $8.37 and FY2028 EPS of $9.15, but retains a “Strong Sell” rating.
• Negative Sentiment: Zacks cut its FY2026 EPS estimate to $8.07 from $8.41 and reduced its Q4 2026 forecast to $1.93 from $2.29. The FY2026 estimate is only slightly above the broader consensus of $8.03, indicating limited near-term earnings upside and creating pressure on the shares.
• Negative Sentiment: The negative revisions follow Maximus’ latest quarterly results, which showed revenue below expectations and a 5.1% year-over-year decline, despite a small EPS beat. With shares still below their 200-day moving average, investors may remain focused on contracting revenue and the risk that government-services demand or contract timing could weigh on earnings.

Maximus Profile

Maximus, Inc (NYSE: MMS) is a global provider of government services focused on delivering health and human services programs. The company partners with federal, state, and local agencies to administer and manage programs that support individuals and families across various stages of life. Key service areas include eligibility determination and enrollment services for Medicaid, Medicare, Children’s Health Insurance Program (CHIP) and other public assistance programs, as well as call center operations, case management and program integrity solutions.